Antifolates can have a role in the treatment of Plasmodium vivax

Trends in Parasitology

Volumn 23, Issue 5, 2007, Pages 213-222

  Hawkins, Vivian N ^a   Joshi, Hema ^b   Rungsihirunrat, Kanchana ^c   Na Bangchang, Kesara ^c   Sibley, Carol Hopkins ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^c THAMMASAT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; PYRIMETHAMINE;

DRUG EFFICACY; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; IN VITRO STUDY; MALARIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW;

ANIMALS; ANTIMALARIALS; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GENOTYPE; HUMANS; MALARIA, VIVAX; MUTATION; PLASMODIUM VIVAX; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME;

PLASMODIUM VIVAX;

EID: 34247211044     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2007.03.002     Document Type: Review

References (66)

1. Mendis K., et al. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64 (2001) 97-106
2. Sina B. Focus on Plasmodium vivax. Trends Parasitol. 18 (2002) 287-289
3. Baird J.K. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48 (2004) 4075-4083
4. Young M.D., and Burgess R.W. Pyrimethamine resistance in Plasmodium vivax malaria. Bull. World Health Organ. 20 (1959) 27-36
5. Snounou G., and White N.J. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends Parasitol. 20 (2004) 333-339
6. Mayxay M., et al. Identification of cryptic coinfection with Plasmodium falciparum in patients presenting with vivax malaria. Am. J. Trop. Med. Hyg. 65 (2001) 588-592
7. Mayxay M., et al. Mixed-species malaria infections in humans. Trends Parasitol. 20 (2004) 233-240
8. Hyde J.E. Drug-resistant malaria. Trends Parasitol. 21 (2005) 494-498
9. Sibley C.H., et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends Parasitol. 17 (2001) 582-588
10. Gregson A., and Plowe C.V. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57 (2005) 117-145
11. Plowe C.V., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 176 (1997) 1590-1596
12. Nzila-Mounda A., et al. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42 (1998) 164-169
13. Mutabingwa T.K., et al. A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 433-438
14. Hyde J.E. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 4 (2002) 165-174
15. Carlton J. The Plasmodium vivax genome sequencing project. Trends Parasitol. 19 (2003) 227-231
16. Baird J.K. Effectiveness of antimalarial drugs. N. Engl. J. Med. 352 (2005) 1565-1577
17. Bzik D.J., et al. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 8360-8364
18. Eldin de Pecoulas P., et al. Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene 211 (1998) 177-185
19. Yuvaniyama J., et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 10 (2003) 357-365
20. Kongsaeree P., et al. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13046-13051
21. Hastings M.D., et al. Novel Plasmodium vivax dhfr alleles from the Indonesian archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob. Agents Chemother. 49 (2005) 733-740
22. Imwong M., et al. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob. Agents Chemother. 45 (2001) 3122-3127
23. Tjitra E., et al. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob. Agents Chemother. 46 (2002) 3947-3953
24. Imwong M., et al. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob. Agents Chemother. 47 (2003) 1514-1521
25. Brega S., et al. Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolates. Antimicrob. Agents Chemother. 48 (2004) 2581-2587
26. Na B.K., et al. Genetic variations of the dihydrofolate reductase gene of Plasmodium vivax in Mandalay division. Myanmar. Parasitol. Res. 96 (2005) 321-325
27. Eldin de Pecoulas P.E., et al. Genetic variation of the dihydrofolate reductase gene in Plasmodium vivax in Snoul, northeastern Cambodia. Acta Trop. 92 (2004) 1-6
28. Kaur S., et al. Plasmodium vivax dihydrofolate reductase point mutations from the Indian subcontinent. Acta Trop. 97 (2006) 174-180
29. Schunk M., et al. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Malar. J. 5 (2006) 54
30. Valecha N., et al. Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern. Trans R Soc Trop Med Hyg (2006)
31. Eldin de Pecoulas P.E., et al. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol. Biochem. Parasitol. 92 (1998) 265-273
32. Hastings M.D., et al. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J. Infect. Dis. 189 (2004) 744-750
33. Cortese J.F., and Plowe C.V. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol. Biochem. Parasitol. 94 (1998) 205-214
34. Brooks D.R., et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224 (1994) 397-405
35. Wang P., et al. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum. Mol. Microbiol. 51 (2004) 1425-1438
36. Hyde J.E., and Sims P.F. Sulfa-drug resistance in Plasmodium falciparum. Trends Parasitol. 17 (2001) 265-266
37. Triglia T., and Cowman A.F. The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resist. Update 2 (1999) 15-19
38. Korsinczky M., et al. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob. Agents Chemother. 48 (2004) 2214-2222
39. Peters W. Chemotherapy and Drug Resistance in Malaria (1987), Academic Press
40. Krotoski W.A., et al. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am. J. Trop. Med. Hyg. 31 (1982) 1291-1293
41. Hernandez T., et al. Studies in human malaria. XXXIV. Acquired resistance to pyrimethamine (daraprim) by the Chesson strain of Plasmodium vivax. Am. J. Trop. Med. Hyg. 2 (1953) 797-804
42. Coatney G.R., et al. Studies in human malaria. XXXII. The protective and therapeutic effects of pyrimethamine (daraprim) against Chesson strain vivax malaria. Am. J. Trop. Med. Hyg. 2 (1953) 777-787
43. Ehrman F.C., et al. Plasmodium vivax Chesson strain. Science 101 (1945) 377
44. Pukrittayakamee S., et al. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop. 89 (2004) 351-356
45. Milhous W.K., et al. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob. Agents Chemother. 27 (1985) 525-530
46. Desjardins R.E., et al. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16 (1979) 710-718
47. Russell B.M., et al. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47 (2003) 170-173
48. Chotivanich K., et al. In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am. J. Trop. Med. Hyg. 70 (2004) 395-397
49. Kocken C., et al. Plasmodium vivax: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. Exp Parasitol (2006)
50. Bunyarataphan S., et al. Evaluation of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays. Antimicrob. Agents Chemother. 50 (2006) 3631-3637
51. Leartsakulpanich U., et al. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol. Biochem. Parasitol. 119 (2002) 63-73
52. Tahar R., et al. Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Mol. Biochem. Parasitol. 113 (2001) 241-249
53. Hastings M.D., and Sibley C.H. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13137-13141
54. Jensen N.P., et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J. Med. Chem. 44 (2001) 3925-3931
55. Imwong M., et al. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob. Agents Chemother. 49 (2005) 4393-4395
56. Djimde A., et al. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344 (2001) 257-263
57. Kublin J.G., et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185 (2002) 380-388
58. White N.J. Why is it that antimalarial drug treatments do not always work?. Ann. Trop. Med. Parasitol. 92 (1998) 449-458
59. Nzila A.M., et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44 (2000) 991-996
60. Mutabingwa T., et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358 (2001) 1218-1223
61. Kyabayinze D., et al. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am. J. Trop. Med. Hyg. 69 (2003) 247-252
62. Staedke S.G., et al. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 9 (2004) 624-629
63. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemother. 57 (2006) 1043-1054
64. Prajapati, S.K. et al. Allele polymorphism in the Plasmodium vivax dihydrofolate reductase (Pvdhfr) gene among Indian field isolates. Clin. Microbiol. Infect. (in press)
65. Hamedi Y., et al. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 35 (2004) 570-574
66. Auliff A., et al. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am. J. Trop. Med. Hyg. 75 (2006) 617-621